Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7354096 | 0.88 | ALDH1A1 (0.31) | — | |
| SCHEMBL1162579 | 0.82 | TRPA1 (0.33) | TRPA1 | |
| SCHEMBL9298 | 0.77 | TRPA1 (0.33) | TRPA1 | |
| Water SCHEMBL8322206 | 0.76 | TRPA1 (0.32) | TRPA1 | |
| SCHEMBL2516591 | 0.71 | TRPA1 (0.36) | TRPA1 | |
| SCHEMBL11531367 | 0.67 | NOS3 (0.33) | TRPA1 | |
| SCHEMBL9728983 | 0.65 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL7947507 | 0.65 | TRPA1 (0.35) | TRPA1 | |
| Bromide SCHEMBL3719760 | 0.64 | TRPA1 (0.34) | TRPA1 | |
| SCHEMBL2518626 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-20 | — | — | US | disclosed |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-07-07 | — | — | US | disclosed |
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-5726172-A | BENZOXAZINONE DERIVATIVES; TREATMENT OF PRETERM LABOR, DYSMENORRHEA | MERCK & CO., INC. (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0450097-A1 | BENZOHETEROCYCLIC COMPOUNDS. | OTSUKA PHARMA CO LTD (JP) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITF, UACA, VEGFA | TRPA1 1580/4885 |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITF, UACA, VEGFA | TRPA1 1580/4885 |
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | TRPA1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.